Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04863261 · ClinicalTrials.gov registry record · NA
Cabenuva Injection Tracking in CHORUS
A NA study, sponsored by Epividian.
- Completed
- Registry status
- NA
- Development phase
- 37
- Enrollment target
NCT04863261 is a NA study that has completed, run by Epividian. The registered enrollment target is 37 participants.
The verdict
NCT04863261, a NA study, has completed, sponsored by Epividian.
- COMPLETED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
Study Summary
This is a cluster randomized trial in which clinics will be randomized to the intervention or the control arm. The purpose of this study is to assess if receiving alerts can help providers manage the scheduling of monthly cabotegravir + rilpivirine long-acting injections for the treatment of HIV.
Interventions
- OTHER Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2022-07-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04863261
The ClinicalTrials.gov registry entry for NCT04863261 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Epividian, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App is the first listed.
NCT04863261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04863261 about?
NCT04863261 is a clinical study titled "Cabenuva Injection Tracking in CHORUS". This is a cluster randomized trial in which clinics will be randomized to the intervention or the control arm. The purpose of this study is to assess if receiving alerts can help providers manage the scheduling of monthly cabotegravir + rilpivirine long-acting injections for the treatment of HIV.
What is the current status of trial NCT04863261?
This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2021-10-01. Estimated completion is 2022-07-07.
What interventions are being tested in trial NCT04863261?
The interventions under investigation include: Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App (OTHER).
Who is sponsoring clinical trial NCT04863261?
This trial is sponsored by Epividian, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.